Abionyx Pharma Sa · EURONEXT:ABNX
Abionyx Pharma Sa — Investor Presentation (March 2026)
16 slides from Abionyx Pharma Sa's investor presentation, March 2026
Slide 1: From a rare-disease clinical validation to blockbuster market authorization
A company selected as a France 2030 laureate From a rare-disease clinical validation to blockbuster market authorization MARCH 2026 - CONFIDENTIAL Cyrille Tupin – CEO Dr Rob Scott MD – CMO, head of R&D CONFIDENTIAL – FOR DISCUSSION PURPOSES ONLY
Slide 2: Disclaimer
Disclaimer You must read the following before continuing. In accessing this document, you agree to be bound by the following terms and conditions. References herein to this presentation (this “Presentation”) shall mean and include this document, the oral presentation accompanying this document provi
Slide 3: Abionyx: Global leader in recombinant apoA-I with transformative clinical efficacy
BREAKTHROUGH Abionyx: Global leader in recombinant apoA-I with transformative clinical efficacy Global leader in recombinant human apoA-I therapies, leveraging over 20 years of lipid metabolism expertise to pioneer 1 the first bioengineered therapy for toxic lipids regulation De-risked regulatory pa
Slide 4: We developed the first bioengineered apoA-I, a breakthrough innovation in toxic lipid regulation
BREAKTHROUGH We developed the first bioengineered apoA-I, a breakthrough innovation in toxic lipid regulation Abionyx is producing CER-001, a human HDL/apoA-I, one of the most abundant protein in human blood, identical in structure and function, overcoming challenges of stability, purity, and large-
Slide 5: CER-001 biotherapy targets the root cause shared by two diseases
APPLICATIONS CER-001 biotherapy targets the root cause shared by two diseases Both LCAT deficiency (genetic, chronic) and Sepsis (acute) lead to a loss of apoA-I, the key complex that clears toxic lipids and controls inflammation. Abionyx is advancing therapies addressing these two indications. apoA
Slide 6: Proven GMP manufacturing process ready to commercial roll-out
PRODUCTION Proven GMP manufacturing process ready to commercial roll-out Since its first successful production in 2015, Abionyx has completed more than 35 batches of CER-001 — the latest in early 2025 — leveraging a France-based network of leading CDMOs. UPSTREAM PROCESS DOWNSTREAM PROCESS COMPLEXAT
Slide 7: Pipeline overview
PIPELINE Pipeline overview Candidate Indication Preclinical Phase I Phase II Phase III MAA Comments ▪ 2 GMP batches to be manufactured in 2026/2027 CER-001 LCAT ▪ EMA submission in 2027 and FDA submission in 2029 CER-001 Sepsis ▪ Phase 2b to be started in 2026 Ophthalmology ABNX-100 ▪ Next steps in
Slide 8: Clinical development completed for LCAT deficiency, a severe disease with no existing treatment
TREATMENT DEVELOPMENT: LCAT DEFICIENCY Clinical development completed for LCAT deficiency, a severe disease with no existing treatment Rare genetic disease leading to 0 approved treatment €200 M market opportunity loss of functional HDL/apoA-I and progressive organ failure: kidney, eye, anemia 1 K+
Slide 9: Outstanding Phase 2a outcomes set a solid foundation for the upcoming Phase 2b
TREATMENT DEVELOPMENT: SEPSIS Outstanding Phase 2a outcomes set a solid foundation for the upcoming Phase 2b Sepsis is a life-threatening immune 0 authorized therapy €27 B market opportunity overreaction that causes organ failure. addressing the root cause Third leading cause of death worldwide, it
Slide 10: A study in Scientific Reports in NATURE demonstrates that higher genetically predicted plasma apoA-I
VALIDATION OF GENETIC CAUSALITY FOR THE MECHANISM OF ACTION (MOA) A study in Scientific Reports in NATURE demonstrates that higher genetically predicted plasma apoA-I causally protects against sepsis incidence and 28-day mortality Publication of the study in Nature Portfolio’s Scientific Reports on
Slide 11: IHU SEPSIS is the World's Leading Center Dedicated to Sepsis
STRATEGIC PARTNER IN SEPSIS: IHU SEPSIS IHU SEPSIS is the World's Leading Center Dedicated to Sepsis to create the first fully integrated global platform dedicated to the treatment of sepsis ABIONYX Pharma entered into advanced strategic discussions with IHU SEPSIS to partner on sepsis treatments on
Slide 12: While LCAT secures a niche market opportunity, Sepsis unlocks the multi-billion-euro upside
MARKET SIZE While LCAT secures a niche market opportunity, Sepsis unlocks the multi- billion-euro upside LCAT* 1K x €200 K = €200 M deficiency Sepsis** 750 K x €36 K = €27 B with AKI # Addressable Avg. Weighted Total Addressable Patients Price Market Size * Total number of addressable patients world
Slide 13: A leadership team with strong equity ownership and recognized scientific and business achievements
TEAM A leadership team with strong equity ownership and recognized scientific and business achievements Cyrille Tupin Dr Rob Scott MD CEO CMO, head of R&D 5 publications with positive clinical results Connie Keyserling Peyrottes Margit Holzer, Ph.D. SVP of Clinical Development SVP of Bio-production
Slide 14: CER-001 is protected until 2042 plus the BLA protection for 10-12 years
INTELLECTUAL PROPERTY CER-001 is protected until 2042 plus the BLA protection for 10-12 years US - 12-year regulatory exclusivity Regulatory standards for patents Europe – 10 + 1 year regulatory exclusivity CRN-001 - Family 1 Charged lipoprotein (LP) complexes EMA approval target - CRN-015 - Family
Slide 15: A Euronext listed biotech with strong liquidity
EQUITY MARKET PROFILE Abionyx (ABNX) — Equity Overview A Euronext listed biotech with strong liquidity LIQUIDITY OWNERSHIP & MARKET DYNAMICS Ticker / Exchange ABNX, Euronext Paris Bpifrance Participations ISIN FR0012616852 4,25% 66 % free float PEA / PME Listing & eligibility €1.3 M+ daily trading t
Slide 16: Thank you.
Thank you. 16 CONFIDENTIAL – FOR DISCUSSION PURPOSES ONLY